// App-Quantinova.ai

e15038 : Docetaxel, cisplatin, and fluorouracil combination in neoadjuvant setting in the treatment of locally advanced gastric adenocarcinoma: A phase II NEOTAX study.

Researchers

Presenter

  • Nuriye zdemir

Principal Investigators

  • Huseyin Abali

  • Burak Civelek

  • Dilek Oguz

  • Birol Bostanci

  • Bulent Yalcin

  • Nurullah Zengin

  • Murat VurAlSuayib Yalcin

  • Berna Oksuzoglu

Medical Centers

  • Ankara Oncology Research and Training Hospital Department of Medical Oncology, Ankara, Turkey

  • Department of Radiology, Ankara Numune Training and Research Hospital, Ankara, TurkeyBaskent University Medical Faculty, Ankara, TurkeyAnkara Numune Training and Research Hospital, Department of Medical Oncology, Ankara, Turkey

  • Department of Medical Oncology, Ankara Ataturk Education and Research Hospital, Ankara, Turkey

  • Hacettepe University Cancer Institute, Department of Medical Oncology, Ankara, Turkey

  • Department of Medical Oncology, Yildirim Beyazit University Faculty of Medicine, Ankara, Turkey

  • Department of Gastroenterology, Turkiye Yuksek Ihtisas Training and Research Hospital, Ankara, Turkey

Locations

  • Turkey

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Metastatic gastric and oesogastric junction (AGC) adenocarcinoma

Biomarkers

  • Circulating tumor cells

Drug/Treatment

  • Fluorouracil

  • Adrucil injection

  • lenograstim

  • Docetaxel

  • Cisplatin

Outcome

  • Positive

Study Design

  • open label

  • single arm

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved